DelveInsight has launched a new report on “Respiratory Syncytial Virus Infections Market”
About Respiratory Syncytial Virus Infections
Respiratory syncytial virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. It is also a significant cause of respiratory illness in older adults.
Request for free sample copy– https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market
The Respiratory Syncytial Virus Infections Market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Respiratory Syncytial Virus Infections Market report
Respiratory Syncytial Virus Infections Symptoms
Symptoms of RSV infection usually include runny nose; decrease in appetite; coughing; sneezing fever; wheezing. These symptoms usually appear in stages and not all at once. In very young infants with RSV, the only symptoms may be irritability, decreased activity, and breathing difficulties. RSV can also cause more severe infections such as bronchiolitis, an inflammation of the small airways in the lung, and pneumonia, an infection of the lungs. It is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age. People infected with RSV usually show symptoms within 4 to 6 days after getting infected.
Respiratory Syncytial Virus Infections Market Research
Researchers are working to develop RSV vaccines, but none are available yet. A drug called palivizumab is available to prevent severe RSV illness in certain infants and children who are at high risk for severe disease. For example, infants born prematurely or with congenital (from birth) heart disease or chronic lung disease. The drug can help prevent serious RSV disease, but it cannot help cure or treat children already suffering from serious RSV disease, and it cannot prevent infection with RSV.
Respiratory Syncytial Virus Infections Key players
Respiratory Syncytial Virus Infections Market Drugs
Respiratory Syncytial Virus Infections Market Report Scope
Table of content
1. Key Insights
2. Executive Summary of Respiratory syncytial virus (RSV)
3. Competitive Intelligence Analysis for Respiratory syncytial virus (RSV)
4. Respiratory syncytial virus (RSV): Market Overview at a Glance
5. Respiratory syncytial virus (RSV): Disease Background and Overview
6. Patient Journey
7. Respiratory syncytial virus (RSV) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Respiratory syncytial virus (RSV) Treatment
11. Marketed Products
12. Emerging Therapies
13. Respiratory syncytial virus (RSV): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Respiratory syncytial virus (RSV)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Reasons to buy
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/